Active Filter(s):
Details:
On the first day after surgery, patients receiving ORAVEXX (cannabidiol, CBD), experienced on average 23% less pain as measured by the Visual Analog Scale (VAS) pain score compared to patients receiving the placebo.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Oravexx
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: NYU Langone Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022